Key result
Human GII.4 and GIV.1 norovirus antibodies occur in ~33% of captive non-human primates.
Why the study?
Data were limited regarding the natural susceptibility of non-human primates to human norovirus infections and potential cross-species transmission.
Cross-Sectional (n=86)
No
Captive non-human primates show natural susceptibility and exposure to human norovirus genogroups GII and GIV.
May support norovirus surveillance in primate facilities; leaves open their role as reservoirs for human strains.
Noroviruses (NoVs) are a major cause of epidemic gastroenteritis in children and adults. Several pieces of evidence suggest that viruses genetically and antigenically closely related to human NoVs might infect animals, raising public health concerns about potential cross-species transmission. The natural susceptibility of non-human primates (NPHs) to human NoV infections has already been reported, but a limited amount of data is currently available. In order to start filling this gap, we screened a total of 86 serum samples of seven different species of NPHs housed at the Zoological Garden (Bioparco) of Rome (Italy), collected between 2001 and 2017, using an enzyme-linked immunosorbent assay (ELISA) based on virus-like particles (VLPs) of human GII.4 and GIV.1 NoVs. Antibodies specific for both genotypes were detected with an overall prevalence of 32.6%. In detail, IgG antibodies against GII.4 NoVs were found in 18 Japanese macaques (29.0%, 18/62), a mandrill (10.0%, 1/10), a white-crowned mangabey (16.6%, 1/6) and in an orangutan (33.3%, 1/3). Twelve macaques (19.3%, 12/62), five mandrills (50.0%, 5/10), two chimpanzees (100%, 2/2) and a white-crowned mangabey (16.6%, 1/6) showed antibodies for GIV.1 NoVs. The findings of this study confirm the natural susceptibility of captive NHPs to GII NoV infections. In addition, IgG antibodies against GIV.1 were detected, suggesting that NHPs are exposed to GIV NoVs or to antigenically related NoV strains.
No takes yet. Share an insight, caveat, or question.
Profio et al. (2019) conducted a cross-sectional in Norovirus infection (n=86). Norovirus genogroups GII and GIV was evaluated on Presence of antibodies specific for GII.4 and GIV.1 NoVs. Antibodies specific for human GII.4 and GIV.1 noroviruses were detected in captive non-human primates with an overall prevalence of 32.6%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: